Project Grant R21CA296504
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $395K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Colorado-Denver to study the role of the EYA3/PP2A protein complex in regulating the metastatic spread of triple-negative breast cancer (TNBC). The $647,118 award, effective March 1, 2025 through February 28, 2030, supports research aimed at understanding how EYA3 and its interaction with the B55A subunit of PP2A contribute to TNBC metastasis. The project...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...
- The National Cancer Institute awarded a $134,274 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Tufts University School of Medicine in Boston, MA. The goal of this 3.5-year project, starting December 1, 2024 and ending June 30, 2028, is to investigate the role of the TRPV1 ion channel in driving increased sensory nerve innervation within triple-negative breast cancer (TNBC) tumors. The research aims to uncover the mechanism by which TNBC cells stimulate...
- This federal Project Grant award of $534,083 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research at the University of California, San Diego (UCSD) to investigate the mechanisms by which breast cancer cell-derived extracellular vesicles induce systemic glucocorticoid signaling and its effects on promoting metastasis. The key goals of the 5-year project are: (1) to identify how cancer cell extracellular vesicles enhance glucocorticoid production, (2) to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....
- This $403,485 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel platinum-based therapeutics that can effectively induce high levels of reactive oxygen species (ROS) to treat triple-negative breast cancer (TNBC). The research, conducted by The Methodist Hospital Research Institute in Texas, aims to create new drug candidates that can rapidly eradicate TNBC cells and suppress tumor growth, particularly in cases...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...